There was no apparent difference in the risk of relapse after blood stem cell and bone marrow transplantation, though the follow-up was relatively short to evaluate this outcome. The 1-year cumulative incidences of relapse among patients with acute leukemia in first remission were 14% (95% CI, 7%-23%) with blood stems cells and 11% (95% CI, 7%-17%) with bone marrow.
Richard E., et al. (2000). ‘Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation’. Blood 95(12): 3702-3709. (RISCEN70)